Shanghai Fosun Pharma Considering $500 Million IPO of Gland Pharma

Published on: July 20, 2018
Author: Amy Liu

Shanghai Fosun Pharma is considering an IPO of one of its recent acquisitions, the Indian drugmaker Gland Pharma, according to a Bloomberg report. If it decides to move ahead on the transaction, Fosun would seek to raise $500 million in an initial offering on an Indian exchange. In 2017, Fosun paid $1.1 billion for 74% ownership of Gland, a company known for its generic injectable products.

Source: China Biotoday

Biotechnology Genomics Healthcare Services Life Science Medical Device Pharmaceutical